Table II.
Secondary functional outcomes: FVC, TUG, QoL.
| Outcome measure | Baseline Mean
|
6-month Mean
|
Mean change in scores
|
p-value Wilcoxon rank-sum test | |||
|---|---|---|---|---|---|---|---|
| Primary analysis (n=60) | Celecoxib/Creatine (n=30) | Minocycline/Creatine (n=30) | Celecoxib/Creatine | Minocycline/Creatine | Celecoxib/Creatine | Minocycline/Creatine | |
| Primary analysis (n=60) | |||||||
| Mean FVC (SD) | 88.90 (13.64) | 94.07 (15.11) | 76.57 (24.81) | 76.00 (31.27) | −12.33 (15.88) | −18.07 (24.75) | 0.482 |
| Mean TUG (SD) n=46 | 20.54 (35.59) | 11.91 (5.89) | 37.27 (56.10) | 36.00 (60.44) | 16.73 (44.53) | 24.09 (57.35) | 0.201 |
| Mean QoL (SD) | 8.20 (1.61) | 7.43 (2.06) | 6.53 (2.16) | 5.87 (2.79) | −1.67 (2.28) | −1.57 (2.87) | 0.589 |
| Secondary analysis (n=86) | Celecoxib/Creatine (n=47) | Minocycline/Creatine (n=39) | Celecoxib/Creatine | Minocycline/Creatine | Celecoxib/Creatine | Minocycline/Creatine | |
| Mean FVC (SD) | 87.96 (15.02) | 92.08 (15.13) | 72.68 (27.23) | 70.51 (33.75) | −15.28 (18.09) | −21.56 (27.02) | 0.342 |
| Mean TUG (SD) | 19.89 (29.98) | 11.26 (5.24) | 53.13 (69.15) | 51.16 (72.43) | 33.24 (61.27) | 39.90 (70.53) | 0.508 |
| Mean QoL (SD) n=72 | 7.83 (1.85) | 7.31 (2.08) | 6.21 (2.47) | 5.72 (3.02) | −1.62 (2.39) | −1.59 (2.90) | 0.728 |
FVC: Forced Vital Capacity; TUG: Timed Up and Go Test; QoL: Quality of Life. Fourteen participants were missing the baseline TUG values and the month 6 values and so were excluded from these analyses.